Bfsg LLC Raises Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Bfsg LLC grew its holdings in Novo Nordisk A/S (NYSE:NVO) by 18.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 102,992 shares of the company’s stock after buying an additional 16,375 shares during the quarter. Novo Nordisk A/S accounts for 1.0% of Bfsg LLC’s investment portfolio, making the stock its 22nd largest position. Bfsg LLC’s holdings in Novo Nordisk A/S were worth $8,859,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the business. Daiwa Securities Group Inc. purchased a new stake in Novo Nordisk A/S in the 3rd quarter worth $28,000. Center for Financial Planning Inc. increased its stake in shares of Novo Nordisk A/S by 72.4% during the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company’s stock worth $25,000 after purchasing an additional 123 shares in the last quarter. Capital Performance Advisors LLP acquired a new position in shares of Novo Nordisk A/S during the 3rd quarter worth about $42,000. Carolina Wealth Advisors LLC purchased a new position in Novo Nordisk A/S in the 3rd quarter valued at about $48,000. Finally, Dunhill Financial LLC boosted its holdings in Novo Nordisk A/S by 196.8% in the 3rd quarter. Dunhill Financial LLC now owns 469 shares of the company’s stock worth $56,000 after buying an additional 311 shares during the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Down 1.1 %

NYSE NVO opened at $77.94 on Tuesday. The business’s fifty day simple moving average is $88.65 and its 200-day simple moving average is $109.54. The company has a quick ratio of 0.75, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. The firm has a market cap of $349.75 billion, a PE ratio of 23.69, a P/E/G ratio of 0.96 and a beta of 0.45. Novo Nordisk A/S has a 52 week low of $77.82 and a 52 week high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. As a group, equities analysts anticipate that Novo Nordisk A/S will post 3.86 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be given a $0.7874 dividend. This represents a yield of 1.2%. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date of this dividend is Monday, March 31st. Novo Nordisk A/S’s dividend payout ratio is presently 21.88%.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on NVO shares. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. BMO Capital Markets lowered their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research note on Monday, December 23rd. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. Finally, Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.